2021-17182. Importer of Controlled Substances Application: Epic Pharma, LLC  

  • Start Preamble

    AGENCY:

    Drug Enforcement Administration, Justice.

    ACTION:

    Notice of application.

    SUMMARY:

    Epic Pharma, LLC. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

    DATES:

    Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before September 13, 2021. Such persons may also file a written request for a hearing on the application on or before September 13, 2021.

    ADDRESSES:

    Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In accordance with 21 CFR 1301.34(a), this is notice that on July 7, 2021, Epic Pharma, LLC., 22715 North Conduit Avenue, Laurelton, New York 11413, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

    Controlled substanceDrug codeSchedule
    Methadone9250II

    The company plans to import the listed controlled substance for research and development purposes.

    Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

    Start Signature

    Brian S. Besser,

    Acting Assistant Administrator.

    End Signature End Supplemental Information

    [FR Doc. 2021-17182 Filed 8-11-21; 8:45 am]

    BILLING CODE P

Document Information

Published:
08/12/2021
Department:
Drug Enforcement Administration
Entry Type:
Notice
Action:
Notice of application.
Document Number:
2021-17182
Dates:
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before September 13, 2021. Such persons may also file a written request for a hearing on the application on or before September 13, 2021.
Pages:
44405-44405 (1 pages)
Docket Numbers:
Docket No. DEA-878
PDF File:
2021-17182.pdf